FDA approves pembrolizumab in combination with chemotherapy for first-line treatment of metastatic squamous NSCLC  

  RSS

Daniel
(@daniel)
New Member Admin
Joined: 3 years  ago
Posts: 212
05/11/2018 1:05 pm  

FDA approved pembrolizumab (KEYTRUDA, Merck & Co. Inc.) in combination with carboplatin and either paclitaxel or nab-paclitaxel as first-line treatment of metastatic squamous non-small cell lung cancer (NSCLC)..More Information.  October 30, 2018


ReplyQuote
Share: